Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients ...

Plozasiran is not yet approved for commercial use in the U.S., but, as Healio previously reported, it received a breakthrough therapy designation from the FDA, and Arrowhead plans to file an ...

"Plozasiran produced significant reductions in triglyceride levels below the threshold associated with elevated risk for pancreatitis," concluded lead investigator Daniel Gaudet, MD, PhD ...

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final ...

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3), which is a component ...

Cardiology > Dyslipidemia Plozasiran Paves RNA Interference Path to Triglyceride Reduction — Clinical outcomes pending for people with elevated LDL cholesterol and triglycerides by Nicole Lou ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to plozasiran for use as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia ...

Plozasiran’s first commercial launch is anticipated by late 2025, pending FDA approval. The drug is positioned as a potential major player in the treatment of familial chylomicronemia syndrome ...

Arrowhead Pharmaceuticals, Inc. today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed ...